# A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

> **NCT00909597** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 756 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** pioglitazone
- **DRUG:** taspoglutide
- **DRUG:** taspoglutide

## Key facts

- **NCT ID:** NCT00909597
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 756 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909597, "A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00909597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*